Scarica l'app Stockscreener
6.88
8.52%
0.54
Dopo l'orario di chiusura:
6.54
-0.34
-4.94%
Precedente Chiudi:
$6.34
Aprire:
$6.28
Volume 24 ore:
928.04K
Relative Volume:
2.08
Capitalizzazione di mercato:
$324.84M
Reddito:
$31.37M
Utile/perdita netta:
$-53.77M
Rapporto P/E:
-4.8342
EPS:
-1.4232
Flusso di cassa netto:
$-49.02M
1 W Prestazione:
+6.67%
1M Prestazione:
-0.72%
6M Prestazione:
-63.60%
1 anno Prestazione:
-57.74%
Intervallo 1D:
$6.16
$7.09
Intervallo di 1 settimana:
$5.96
$7.09
Portata 52W:
$5.81
$27.72
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Nome
Silence Therapeutics Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta SLN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
6.88 | 324.84M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-09-03 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Borsa (SLN) Ultime notizie
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com
Silence Therapeutics' SWOT analysis: RNAi stock poised for growth amid clinical progress - Investing.com India
Silence Therapeutics announces additional results from SANRECO study - TipRanks
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - MSN
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Yahoo Finance
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks
SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks
Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Silence Therapeutics: Rising Assets Amid Growing Losses - TipRanks
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance
It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News
Silence Therapeutics Plc ADR (SLN) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
What Did We Find About Insider Trading At Silence Therapeutics Plc ADR (NASDAQ: SLN)? - Stocks Register
Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data - Investing.com UK
H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results By Investing.com - Investing.com South Africa
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years - Yahoo Finance
How did Silence Therapeutics Plc ADR (SLN) fare last session? - US Post News
Ratio Revelations: Silence Therapeutics Plc ADR (SLN)’s Financial Metrics in the Spotlight - The Dwinnex
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny - US Post News
Market Insight: Silence Therapeutics Plc ADR (SLN)’s Notable Drop, Closing at 16.70 - The Dwinnex
The 3 Best Gene Editing Stocks to Buy in August 2024 - Markets Insider
It would be worthwhile to take a closer look at Silence Therapeutics Plc ADR (SLN) - US Post News
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny – US Post News - US Post News
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com India
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics - Yahoo Lifestyle UK
Hardman & Co Insight: Survival of the UK life sciences sector - Research Tree
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Altria maintains stock target, Buy rating on FDA move By Investing.com - Investing.com UK
Zerlasiran shows promise in phase 2 study for cardiovascular risk By Investing.com - Investing.com
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates - Yahoo Finance
Kirby Corp CEO sells shares worth over $360k By Investing.com - Investing.com
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - MSN
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Silence Therapeutics Plc ADR (SLN-Q) QuotePress Release - The Globe and Mail
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation - Yahoo Finance
Silence Therapeutics A Quieter Name In RNAi (NASDAQ:SLN) - Seeking Alpha
Silence Therapeutics Plc Adr Azioni (SLN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):